SCP Vitalife Partners

SCP Vitalife Partners is a venture capital firm specializing in life sciences investments in Israel and the United States. The firm manages $230 million across two funds and has made over 30 investments in life sciences startups. SCP Vitalife focuses on companies with breakthrough products that address current medical needs and are protected by strong intellectual property. The team comprises seasoned professionals with backgrounds as entrepreneurs, senior operating executives, clinical practitioners, and technologists, providing hands-on assistance to portfolio companies and leveraging established strategic partner relationships to build successful businesses.

The firm's investment strategy targets early- to mid-stage life science companies with exceptional technology or proprietary advantages poised to capitalize on major market trends. SCP Vitalife's typical initial investment size ranges from $3 million to $7 million, with total investments of $7 million to $15 million over the lifespan of the investment. The firm allocates over half of its capital to Israeli companies or those with significant R&D and operational ties to Israel, while the remainder is invested in U.S.-based companies.

SCP Vitalife has a strong track record of supporting innovative companies in the life sciences sector. Notable investments include ReWalk Robotics, a developer of wearable robotic exoskeletons for individuals with lower limb disabilities, and Regentis Biomaterials, a company specializing in tissue engineering products for cartilage regeneration. These investments highlight SCP Vitalife's commitment to advancing medical technologies that address critical healthcare challenges.